Sequenom Reports Preliminary 2012 Performance Results

Sequenom, Inc.

, a life sciences company providing innovative diagnostic testing and genetic analysis solutions, today announced preliminary highlights of the Company's 2012 performance and accomplishments. Initial 2012 Performance Results (unaudited) Total revenue of approximately $89 million, growth of approximately 59 percent year-over-year for 2012 Diagnostic services revenues of approximately $46 million, compared to $8.3 million in 2011.  Diagnostic services revenues continue to be recorded primarily as cash is received Sales in the Genetic Analysis business of approximately $43 million More than 92,000 total prenatal and retinal diagnostic tests accessioned during the year Strong increases in the adoption rate and sales of Sequenom Center for Molecular Medicine's (Sequenom CMM) MaterniT21 PLUS lab-developed test (LDT): More than 60,000 MaterniT21 PLUS tests accessioned in 2012 An annualized run rate of more than 120,000 MaterniT21 PLUS tests accessioned at the end of 2012 Approximately 56 million lives under coverage with growing number of payor contracts Continued reimbursement as an out-of-network laboratory from large commercial payors